No edit summary |
No edit summary |
||
| Line 100: | Line 100: | ||
[[file:LHF.jpg|center]] | [[file:LHF.jpg|center]] | ||
='''France'''= | |||
=='''[http://www.academie-medecine.fr/lacademie-nationale-de-medecine-rappelle-les-avantages-prouves-et-les-inconvenients-indument-allegues-de-la-cigarette-electronique-vaporette/?lang=en French National Academy of Medicine]'''== | |||
[[file:FNAM.jpg|center]] | |||
=='''[https://www.e-cancer.fr/Comprendre-prevenir-depister/Reduire-les-risques-de-cancer/Tabac/La-cigarette-electronique?fbclid=IwAR1XP0pxDnlQgW9MDqSxJNpKsLsphNOLl_s4O3DfO5CUPKaS_tZzjqfn1lg French National Cancer Institute]'''== | |||
[[file:INCF.jpg|center]] | |||
=='''[https://www.hcsp.fr/Explore.cgi/AvisRapportsDomaine?clefr=591 French High Council for Public Health]'''== | |||
[[file:FHCPH.jpg|center]] | |||
=='''[https://twitter.com/AcadPharm/status/1156249181390036992 French National Academy of Pharmacy]'''== | |||
[[file:FNAP.jpg |center]] | |||
==Collège de la médecine générale (College of General Medicine)== | |||
*[https://web.archive.org/web/20220314183356/https://www.jim.fr/medecin/debats/interview/e-docs/cmg_un_congres_feu_dartifice_interview_du_pr_paul_frappe_191557/document_interview.phtml Source] | |||
“Concerning the electronic cigarette, we consider it as a risk reduction tool and believe that we should not discourage the smoking patient who is learning to vape with a view to weaning [reducing smoking] by indicating to him that it is necessary to avoid the use concomitant cigarette/e-cigarette.” | |||
------------------------ | ------------------------ | ||
='''New Zealand''' (See Also: "Australia and New Zealand")= | ='''New Zealand''' (See Also: "Australia and New Zealand")= | ||
| Line 151: | Line 167: | ||
=='''[https://www.rsph.org.uk/about-us/news/new-phe-review-strengthens-consensus-on-harm-reduction-role-of-e-cigarettes.html Royal Society for Public Health]'''== | =='''[https://www.rsph.org.uk/about-us/news/new-phe-review-strengthens-consensus-on-harm-reduction-role-of-e-cigarettes.html Royal Society for Public Health]'''== | ||
[[file:RSPH.jpg|center]] | [[file:RSPH.jpg|center]] | ||
=='''[https://www.wales.nhs.uk/sitesplus/documents/888/FINAL%20APPROVED%20ENDS%20Position%20Statement%20V1%200.docx Public Health Wales]'''== | =='''[https://www.wales.nhs.uk/sitesplus/documents/888/FINAL%20APPROVED%20ENDS%20Position%20Statement%20V1%200.docx Public Health Wales]'''== | ||
| Line 190: | Line 203: | ||
=='''[https://pubmed.ncbi.nlm.nih.gov/30573147/ American College of Preventive Medicine]'''== | =='''[https://pubmed.ncbi.nlm.nih.gov/30573147/ American College of Preventive Medicine]'''== | ||
[[file:ACPM.jpg|center]] | [[file:ACPM.jpg|center]] | ||
=='''[https://www.entnet.org/content/position-statements-e-cigarettes American Academy of Otolaryngology-Head and Neck Surgery]'''== | =='''[https://www.entnet.org/content/position-statements-e-cigarettes American Academy of Otolaryngology-Head and Neck Surgery]'''== | ||
[[file:AAOHNS.jpg|center]] | [[file:AAOHNS.jpg|center]] | ||
=='''[https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/e-cigarettes Royal Pharmaceutical Society]'''== | =='''[https://www.rpharms.com/recognition/all-our-campaigns/policy-a-z/e-cigarettes Royal Pharmaceutical Society]'''== | ||
| Line 229: | Line 236: | ||
=='''[https://www.bfr.bund.de/en/press_information/2019/39/_vaping___the_bfr_advises_against_self_mixing_e_liquids-242872.html German Federal Institute for Risk Assessment]'''== | =='''[https://www.bfr.bund.de/en/press_information/2019/39/_vaping___the_bfr_advises_against_self_mixing_e_liquids-242872.html German Federal Institute for Risk Assessment]'''== | ||
[[file:BfR.jpg|center]] | [[file:BfR.jpg|center]] | ||
=='''[https://publications.parliament.uk/pa/cm201719/cmselect/cmsctech/505/505.pdf House of Commons Science and Technology Committee (UK)]'''== | =='''[https://publications.parliament.uk/pa/cm201719/cmselect/cmsctech/505/505.pdf House of Commons Science and Technology Committee (UK)]'''== | ||
| Line 257: | Line 263: | ||
=='''[https://www.cancerresearchuk.org/sites/default/files/e-cigarette_briefing_july_2018_final.pdf?utm_source=t.co&utm_medium=referral Cancer Research UK]'''== | =='''[https://www.cancerresearchuk.org/sites/default/files/e-cigarette_briefing_july_2018_final.pdf?utm_source=t.co&utm_medium=referral Cancer Research UK]'''== | ||
[[file:CRUK.jpg|center]] | [[file:CRUK.jpg|center]] | ||
=='''[https://clincancerres.aacrjournals.org/content/21/3/514 American Association for Cancer Research and American Society of Clinical Oncology]'''== | =='''[https://clincancerres.aacrjournals.org/content/21/3/514 American Association for Cancer Research and American Society of Clinical Oncology]'''== | ||
edits